Skip to main content

What the FDA labels say about taking them together

Cobicistat and propafenone

Cobicistat's FDA label of February 10, 2026 names propafenone in its drug interactions section; the propafenone label PlainMeds reads does not name cobicistat. The cobicistat label: “Clinical monitoring is recommended upon coadministration with antiarrhythmics.”

Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the propafenone FDA label on DailyMed (effective September 1, 2025, Strides Pharma Science Limited).

What does the cobicistat label say about propafenone?

Cobicistat label, drug interactions

Concomitant Drug Class/Drug Name: Other antiarrhythmics: e.g., amiodarone disopyramide flecainide mexiletine propafenone quinidine; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ antiarrhythmics; Clinical Comment: Clinical monitoring is recommended upon coadministration with antiarrhythmics.

Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed

What does the propafenone label say about cobicistat?

Propafenone's label (effective September 1, 2025) does not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (PROPAFENONE HYDROCHLORIDE), Strides Pharma Science Limited, effective September 1, 2025 (SPL set c65253ab-937f-4982-b841-69c2b9f9ccdb), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Cobicistat generic labelers
14Propafenone generic labelers
CobicistatPropafenone
Labeled forHIVAtrial fibrillation
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.115 per tablet 150 mg tablet
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?